Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 133-136

  Ma, Hong ^a   Jia, Jidong ^a  

^a School of Basic Medical Science   (China)

Author keywords

Chronic hepatitis B; Nucleoside analogues; Nucleotide analogues; Resistance; Roadmap; Treatment

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; LIVER FIBROSIS; LIVER NECROSIS; LONG TERM CARE; NONHUMAN; REVIEW; SEROCONVERSION; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872012391     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12065     Document Type: Review

References (29)

1. Wang Y, Jia J. Control of hepatitis B in China: prevention and treatment. Expert Rev Anti Infect Ther 2011; 9: 21-5.
2. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-38.
3. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? Liver Int 2012; 32: 1333-41.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
5. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
6. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
7. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591-9.
8. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49(Suppl. 5): S185-95.
9. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12: 341-53.
10. Hou J, Ren H, Wang Y, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population in a real-life setting in China. Hepatol Int 2011; 5: 146.
11. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011; 31: 676-84.
12. You H, Wu X, Ou X, et al. Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced? Antivir Ther 2011; 16: 299-307.
13. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-5110.;21;22
15. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
16. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
17. Hou J, Xu D, Shi G, et al. Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammation and fibrosis regression in patients with chronic hepatitis B [abstract]. J Hepatol 2011; 54(Suppl. 1): S287.
18. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
19. Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49-56.
20. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
21. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54: 91-100.
22. Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011; 31: 755-61.
23. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-41.
24. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-54.
25. Hou J, Sun J, Xie Q, et al. viralogical breakthroght and genotypic resistance in a randomized, controlled study on telbivudine treatment applying roadmap concept in CHB: W76 interim analysis of EFFOTRT study. J Hepatol 2012; 56(Suppl. 1): S203-4.
26. Piratvisuth T, Komolmit P, Tanwandee T, et al. 2-year results of tebivudine (LdT) roadmap study verify the optimal efficacy and safety results in HBeAg positive chronic hepatitis B(CHB) patients. J Hepatol 2012; 56(Suppl. 2): S214.
27. Wang L, Liu F, Liu YD, et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat 2010; 17: 298-304.
28. Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010; 51: 415-21.
29. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011; 26(Suppl. 1): 131-7.